Platelet therapies have been demonstrated to enhance wound healing and tissue regeneration, through the secretion and action of beneficial growth factors such as platelet-derived growth factor (PDGF), epithelial growth factor (EGF) and transforming growth factor (TGF). However, currently these therapies are inconsistent and difficult to use. CTL has the solved technical hurdles for providing a consistent wound care product that is quality controlled, cost effective, and convenient to use.
CTL has developed a cGMP compliant method to produce platelet therapies safely and reproducibly. Stringent quality controls ensure high quality, consistent, and contamination free platelet therapies. Precise quantification of product component ensures standardized product. Additionally, an automated wound healing assay has been developed to confirm efficacy from each lot produced.
Clinical trials commenced in Q4 2014 and are scheduled to complete in 2015.
CTL’s one-step application formulations will save significant physician time in the clinic. The current autologous platelet therapy kits available on the market can take up to one hour to produce the therapy in the clinic. CTL’s therapies are activated and placed onto the wounds in significantly less time.